This task is particularly important and of cancer-relevance because of the following reasons: (i) the EGFR signalling pathway is highly de-regulated in many human cancers and is an attractive target for anti-tumour therapy, (ii) anti-EGFR therapy are only effective to certain patients, (iii) a correlation is often lacking between EGFR expression and tumour responsiveness to anti-EGFR treatments, and (iv) previously overlooked nuclear EGFR pathway is linked to aggressive tumour biology. Here, EGFR is linked to cancer.